Elena Feinstein

Chief Scientist at Dexoligo Therapeutics


An R&D specialist with more than a 20-year of experience in leading cross-functional scientific teams in the biopharmaceutical industry including more than 15 years in the field of siRNA therapeutics discovery and development. A scientific leader with medical, drug development and molecular and cellular biology backgrounds, deep understanding of disease pathogenesis, biological processes, and molecular pathways, strong communication skills, visibility in the oligonucleotide drug development society and a proven record of drug development oversight.

Authored dozens of publications in peer-reviewed journals including Nature, Science, Nature Medicine, Genes & Development, PNAS, Nucleic Acid Research and Molecular Therapy. An inventor on numerous awarded patents and patent applications.

Member of Senior Executive Management Team reporting to CEO.

Experience in:

ü  Defining R&D strategy.

ü  Design and execution of drug discovery, translational research, toxicology and DMPK programs and individual studies in house and in CRO; work with consultants; budgeting.

ü  Being an “interface” between non-clinical and clinical drug development teams.

ü  Preparation of chapters for IND, NDA and other regulatory data packages and documents for regulatory submissions.

ü  Preparation of scientific proposals and technical data packages (that led to multimillion deals on drug target discovery with 8 pharmaceutical companies, siRNA out-licensing deals with 3 pharmaceutical companies, contracts with BARDA and DoD, and awarded grants from granting agencies).

ü  Selection and oversight of CRO and academic collaborations.

ü  Scientific and technical support of Business Development, evaluation of in-licensing opportunities, handling of scientific aspects of due-diligences. Biological guidance for bioinformaticians in software development.

Join Newsletter

© Ciencie Meetings 2024. All rights reserved